Dr Doug Gurr
Chair of the Board of Trustees
Doug Gurr is Amazon UK Country Manager. He joined Amazon in 2011 and was China Country Manager from 2014 to 2016. Prior to Amazon, he was a senior executive and board member at Wal-Mart’s UK operations, Asda Stores Ltd., after founding an Internet startup and working as a Partner at McKinsey & Co. Doug Gurr has two degrees in Mathematics from the University of Cambridge, and a Doctorate degree in Computing from the University of Edinburgh.
Outside work, Doug is Chairman of the British Heart Foundation, a Trustee of the Landmark Trust, and was until 2014 Chairman of the Science Museum Group.
Doug is married with two children, lives in London and Yorkshire, and in his spare time has completed 12 Ironman triathlons and completed over 20 first ascents or ski descents including the first winter ascent of the highest mountain in the arctic.
Andrew Balfour LLB
Andrew Balfour is a retired solicitor who now spends his time working for a number of charities and educational institutions.
He retired from the international law firm Slaughter and May in 2011 after a career of over thirty years working for the firm. During that career he worked on a range of commercial transactions, but was primarily a financing lawyer advising on major borrowing transactions for many leading corporate and bank clients in the UK and elsewhere.
Andrew became a partner of Slaughter and May in 1988, worked in the firm’s New York office for a couple of years in the early 1990s and became head of the financing practice and a member of the partnership board in 2004. Since 2014 Andrew has been Chairman of the firm’s Africa Practice Group, a part time role that requires him to travel extensively in Africa.
In addition to his role for the BHF, Andrew is a trustee of Sustrans (the sustainable transport charity which continues to develop the National Cycle Network) and of Farleigh Hospice in Essex and is also a school governor.
In his spare time Andrew and his wife, Anne, enjoy being outside in the fresh air in Essex, where they live. They have supported the BHF for many years, following in the footsteps of Anne’s mother who was a leading fundraiser for the BHF in Winchester in the 1970s and 1980s. Andrew also enjoys watching sport, going to the theatre and cinema, gardening and walking and cycling in the countryside.
Andrew joined the Board of Trustees in 2012, and is a member of the Audit & Risk Committee.
Professor Dame Anna F Dominiczak DBE MD FRCP FRSE FMedSci
Professor Anna Dominiczak (OBE, MD, FRCP, FRSE, FMedSci) is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences at the University of Glasgow as well as honorary consultant physician and non-executive member of the NHS Greater Glasgow and Clyde Health Board.
One of the world’s leading cardiovascular scientists and clinical academics, Prof Dominiczak’s major research interests are in hypertension, cardiovascular genomics and precision medicine where she has not only published extensively in top peer-reviewed journals (total of 370 publications), but also excelled in large scale research funding for programmes and infrastructure alike (total value £70 million in the last 4 years). She has led a collaboration of four universities and four academic NHS Health Boards across Scotland to develop public/private partnership in Precision Medicine with a current value of £20 million.
Prof Dominiczak is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh, the American Heart Association and the European Society of Cardiology.
She has published over 370 peer reviewed papers in top journals and is an immediate past President of the European Society of Hypertension and Editor-in-Chief of Hypertension, the journal of American Heart Association. In 2005 she was awarded OBE for services to medicine.
Dr Robert Easton BSc ARCS DPhil
Chair of the Fundraising Board
Dr Robert Easton is a Partner and Senior Advisor to The Carlyle Group, the major global alternative asset manager. He was previously head of the firm’s private equity fund in Ireland, Co-Head of Carlyle Europe Technology Partners, a fund targeting Europe-wide growth capital and buyout transactions in the media, software, telecom and healthcare sectors, and prior to that he ran the firm’s UK buyout activities. He is based in London and has been with Carlyle for 16 years.
Prior to joining Carlyle, Dr Easton was Vice President of Corporate Development at Invensys plc. He was a key figure in the mid-nineties transformation of BTR from a diversified conglomerate to a focused engineering group and, following the merger of BTR and Siebe to form Invensys in 1999, in the further focusing of Invensys to become a leading Automation and Controls group.
Dr Easton joined BTR in 1996 from Trafalgar House, another major UK engineering group where he was Director of Corporate Finance and Planning. Prior to this he spent eight years in the investment banking business working initially for CSFB and then for Wasserstein Perella.
Dr Easton has a first class honours degree in chemistry from Imperial College in London and a Doctorate in organic synthesis from Oxford University.
In addition to his Directorships of Carlyle portfolio companies and numerous private company start-ups, Dr Easton is a past Chairman of the British Venture Capital Association, the trade association for private equity in the UK, and he currently sits on two boards at Imperial College, the Advisory Board of the Business School and the private sector Syndicate over-seeing the development if a new University campus at Imperial West. Dr Easton is also a Non-Executive Director of Imperial Innovations, the public company venture capital spin-out entity of Imperial College.
Robert became a Trustee in 2013, he is also Chair of the BHF Fundraising Board, and a member of the Remuneration and Investment Committees.
Dr Evan Harris BM BCh MA (Oxon)
Evan Harris studied physiological sciences at Wadham College, Oxford and qualified in medicine in 1991. After training in general medicine with the Nuffield Department of Medicine at the Oxford Radcliffe Hospital, he worked in public health medicine.
He was MP for Oxford West and Abingdon from 1997 until 2010, a member of the Science and Technology Select Committee and Liberal Democrat Science spokesman from 2003.
He is currently an Honorary Senior Research Fellow at Queen Mary, University of London, and writes on science and medicine for the Guardian and the British Medical Journal.
Evan joined the Board of Trustees in 2011.
Richard Hytner MA LLM
Richard, a law graduate from St John’s College, Cambridge University. Until he established, in 2016, beta baboon, a creative management consultancy helping leadership teams to outperform their ambitions, Richard was Saatchi & Saatchi’s Worldwide Deputy Chairman. He joined Saatchi & Saatchi in 2003 as Chairman and CEO for Europe, Middle East and Africa, having graduated with distinction as a Sloan Fellow from London Business School where he is now Adjunct Associate Professor of Marketing, teaching MBA and Executive Education participants on topics that include Leading strategic transformation; strategic branding; communications; and creativity.
Richard is a trustee of Planting Promise, a sustainable educational enterprise in Sierra Leone; co- founder of the Manchester United Supporters’ Trust; and a non executive adviser to the Management Board of the Metropolitan Police.
Richard published Consiglieri: Leading from the Shadows, a celebration of those who make leadership contributions from beyond the CEO’s office.
Richard joined the Board of Trustees in 2011 and is a member of the Nominations Committee.
Professor John P Iredale
John Iredale is Pro Vice Chancellor Health at the University of Bristol. He holds the chair of Experimental Medicine, and his areas of leadership and responsibility are for the research, teaching and management strategy for the Schools of Medicine, Veterinary Medicine, Dentistry and Biomedical Sciences across the relevant Faculties at the University of Bristol.
He also holds Honorary Consultant contracts with the North Bristol NHS Trust and the University Hospitals Bristol Foundation Trust. Previously Professor Iredale was the Regius Chair of Medical Science, Dean of Clinical Medicine and Vice Principal Health Services at the University of Edinburgh where he led the Medical School. He has previously held the Chair of Medicine in Edinburgh (2006-2013), the chair of Medicine at the University of Southampton (2004-2006) and a Personal Chair in Hepatology (2000-2004). From 2010 to 2016, Prof Iredale was a Non-Executive Director of NHS Lothian.
Professor Iredale graduated from the University of Southampton with honours in Clinical Distinction in 1985 and was awarded a DM in 1995. He was made a Fellow of the Royal College of Physicians of London in 1999 and The Royal College of Physicians of Edinburgh in 2007. He was made a Fellow of the Academy of Medical Sciences in 2003 and Fellow of the Royal Society of Edinburgh in 2011.
Professor Iredale joined the Board of Trustees in November 2016.
Professor David Lomas
Professor David Lomas PhD, ScD, FHEA, FRCP, FMedSci is Vice Provost (Health), Head of UCL School of Life and Medical Sciences and Head of UCL Medical School. He is the Academic Director of the UCL Partners Academic Health Sciences Centre.
David is an NIHR Senior Investigator and works as a respiratory physician at UCLH and the Royal Free Hospital. He was Chair of the Population and Systems Medicines Board at the Medical Research Council and previously chaired the Respiratory Therapy Area Unit Board at GlaxoSmithKline.
David chaired the Scientific Priorities Committee for the 100,000 genomes project and serves as Deputy Chair of the Scientific Advisory Committee for Genomics England. He was a member of the Expert Advisory Group for the UK Minister of Life Sciences Innovative Medicines and MedTech Review.
Professor Lomas joined the Board of Trustees in November 2016.
Chair of the Audit & Risk Committee
Iain Mackay is Group Finance Director of HSBC Holdings Plc, a role he has held since December 2010. Iain joined HSBC in 2007 as CFO of HSBC North America Holdings Inc where he was instrumental in the restructuring of HSBC's consumer finance business. From 2009-2010 he was CFO Asia Pacific of HSBC Holdings Plc. Before joining HSBC, Iain was at General Electrics - initially as Controller of the Global Consumer Finance unit, then CFO of GE Healthcare - Global Diagnostic Imaging. From 1990-1996, Iain was a regional finance director with Schlumberger Dowell. Early in his career, Iain was with PriceWaterhouse in New York and Paris and Thomson McLintock, KMG in the UK.
Iain joined the Board of Trustees in 2015, and is Chair of the Audit & Risk Committee.
Professor Sussan Nourshargh PhD FMedSci FBPhS
Sussan Nourshargh is a pharmacologist who studied at University College London and King’s College London and became Professor of Immunopharmacology at Imperial College London in 2006. In 2007 she joined Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, to establish and head a new Centre focusing on Microvascular Research. Her research aims to unravel the molecular and cellular events involved in leukocyte trafficking and through the application of advanced in vivo imaging modalities her team have made seminal contributions to the fields of inflammation and vascular biology.
Professor Nourshargh is a Wellcome Trust Investigator and Fellow of the Academy of Medical Sciences and British Pharmacological Society. She has acted on numerous funding Boards including BHF Project Grant and Fellowship Committees and is currently member of the Wellcome Trust’s Biomedical Resources & Multi-User Equipment Grant Committee, Royal Society’s Newton Advanced Fellowship Panel, Academy of Medical Sciences SpringBoard Grant Scheme and she chairs the Academy of Medical Sciences Committee for selection of new Fellows in the fields of pharmacology, physiology and neurosciences. Sussan has also been on the panel of numerous national and international scientific advisory boards, has been recipient of several prestigious scientific awards and has held a number of editorial positions.
Professor Nourshargh joined the Board of Trustees in 2015.
Peter received his MA from Cambridge in Philosophy and, recently, an Advanced Diploma in History from Oxford.
Peter has spent 30 years in the media industry, holding board positions in the UK, USA, India and Australia. For many years he was a Board Director of BBC Worldwide Ltd, for whom he developed and ran BBC Magazines; he was also President and CEO of BBC Worldwide Americas Inc, launching some TV channels and chairing a joint venture with Discovery Inc.
Peter was recently Deputy Chairman of Immediate Media Co, a large PE-backed magazine and digital company and is currently Chairman of Texere Publishing, a VC-backed cross-media publisher for the science and medical markets, Chairman of Bell, an education business and he sits on the Board of The National Archives. Peter also Chairs Wildscreen, a media-related conservation charity and has founded East West Relations Ltd. to help western media companies identify and secure opportunities in India, where he was born.
Peter has competed in many triathlons and is these days more of a cyclist, cycling the length of Britain and in sportives.
Peter has had his own heart issues in the past, undergoing a heart bypass in 2011 following a heart attack.
Professor Simon Ray
Simon Ray graduated in Pharmacology (1980) and Medicine (1983) from Bristol University. After early training in general medicine he completed an MD as a BHF funded research fellow with Professor Henry Dargie in Glasgow and then undertook specialist cardiology training in Newcastle, Liverpool and Vancouver. He was appointed consultant cardiologist at the University Hospitals of South Manchester in 1995 and Honorary Professor of Cardiology at the University of Manchester in 2011.
He has served as the President of the British Society of Echocardiography, Vice-President for Clinical Standards of the British Cardiovascular Society and is currently President of the British Heart Valve Society. He has wide ranging clinical interests within cardiology and his research interests are centred on heart valve disease.
Dr Ray joined the Board of Trustees in 2014.
Professor Liam Smeeth MBChB FRCGP FFPH FRCP MSc PhD
Liam Smeeth is professor of clinical epidemiology and Head of the Department of Non-communicable Disease Epidemiology at the London School of Hygiene and Tropical Medicine. He also undertakes clinical work as a general practitioner in north London.
Much of his research is based on making better use of computerised clinical data both to investigate drug effects and disease aetiology. He holds a Wellcome Trust Senior Fellowship in Clinical Science and is Deputy Director of the Farr Institute London, one of the four UK Health Informatics Research Centres. His work is largely in cardiovascular disease, with one area of particular interest being the causal role of infections and inflammation. Other areas of interest are genetic epidemiology and non-communicable diseases in low income settings. He is involved in a range of activities for NICE and the NHS more widely.
Liam joined the Board of Trustees in 2014.
Professor Sir Kent Woods MA MD SM FRCP FMedSci
Vice Chair of the Board of Trustees and Chair of the Advisory Council
Sir Kent Woods was the Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA) 2004-2013 and Chairman of the Management Board of the European Medicines Agency 2011-2015. He was previously Director of the NHS Health Technology Assessment Programme (1999-2003), commissioning research in and for the NHS.
A graduate of Cambridge and of Harvard School of Public Health, he was a consultant physician in cardiovascular medicine at Leicester Royal Infirmary from 1984-2003 and is Emeritus Professor of Therapeutics at Leicester University. He is a Fellow of the Academy of Medical Sciences and was knighted for services to healthcare in 2011.
Sir Kent joined the Board as Vice Chair in 2015. He is also Chair of the Advisory Council, and a member of the Nominations and Remunerations Committees.